Trial: 201912013

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Phase

I/II

Principal Investigator

Dipersio, John

Disease Site

Leukemia, other; Lymphoid Leukemia; Myeloid and Monocytic Leukemia

Learn more about this study at: clinicaltrials.gov